|
1
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rini BI, Rathmell WK and Godley P: Renal
cell carcinoma. Curr Opin Oncol. 20:300–306. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Motzer RJ, Bander NH and Nanus DM:
Renal-cell carcinoma. N Engl J Med. 335:865–875. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Itsumi M and Tatsugami K: Immunotherapy
for renal cell carcinoma. Clin Dev Immunol. 2010:2845812010.
View Article : Google Scholar
|
|
5
|
Pantuck AJ, Zisman A and Belldegrun AS:
The changing natural history of renal cell carcinoma. J Urol.
166:1611–1623. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Singer EA, Gupta GN, Marchalik D and
Srinivasan R: Evolving therapeutic targets in renal cell carcinoma.
Curr Opin Oncol. 25:273–280. 2013.PubMed/NCBI
|
|
7
|
Yang L, Wu Q, Xu L, Zhang W, Zhu Y, Liu H,
Xu J and Gu J: Increased expression of colony stimulating factor-1
is a predictor of poor prognosis in patients with clear-cell renal
cell carcinoma. BMC Cancer. 15:672015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ferchichi I, Kourda N, Sassi S, Romdhane
KB, Balatgi S, Cremet JY, Prigent C and Elgaaied AB: Aurora A
overexpression and pVHL reduced expression are correlated with a
bad kidney cancer prognosis. Dis Markers. 33:333–340. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Song S, Wu Z, Wang C, Liu B, Ye X, Chen J,
Yang Q, Ye H, Xu B and Wang L: RCCRT1 is correlated with prognosis
and promotes cell migration and invasion in renal cell carcinoma.
Urology. 84(3): 7302014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pastore AL, Palleschi G, Silvestri L,
Moschese D, Ricci S, Petrozza V, Carbone A and Di Carlo A: Serum
and urine biomarkers for human renal cell carcinoma. Dis Markers.
2015:2514032015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vitari AC, Leong KG, Newton K, Yee C,
O'Rourke K, Liu J, Phu L, Vij R, Ferrando R, Couto SS, et al: COP1
is a tumour suppressor that causes degradation of ETS transcription
factors. Nature. 474:403–406. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu S, Tong M, Huang J, Zhang Y, Qiao Y,
Weng W, Liu W, Wang J and Sun F: TRIB2 inhibits Wnt/β-Catenin/TCF4
signaling through its associated ubiquitin E3 ligases, β-TrCP, COP1
and Smurf1, in liver cancer cells. FEBS Lett. 588:4334–4341. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sawada G, Ueo H, Matsumura T, Uchi R,
Ishibashi M, Mima K, Kurashige J, Takahashi Y, Akiyoshi S, Sudo T,
et al: Loss of COP1 expression determines poor prognosisin patients
with gastric cancer. Oncol Rep. 30:1971–1975. 2013.PubMed/NCBI
|
|
14
|
Ouyang M, Wang H, Ma J, Lü W, Li J, Yao C,
Chang G, Bi J, Wang S and Wang W: COP1, the negative regulator of
ETV1, influences prognosis in triple-negative breast cancer. BMC
Cancer. 15:1322015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shao J, Teng Y, Padia R, Hong S, Noh H,
Xie X, Mumm JS, Dong Z, Ding HF, Cowell J, et al: COP1 and GSK3β
cooperate to promote c-Jun degradation and inhibit breast cancer
cell tumorigenesis. Neoplasia. 15:1075–1085. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wei W and Kaelin WG Jr: Good COP1 or bad
COP1? In vivo veritas. J Clin Invest. 121:1263–1265. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
18
|
Li Z, Tian T, Lv F, Chang Y, Wang X, Zhang
L, Li X, Li L, Ma W, Wu J and Zhang M: Six1 promotes proliferation
of pancreatic cancer cells via upregulation of cyclin D1
expression. PLoS One. 8:e592032013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Marine JC: Spotlight on the role of COP1
in tumorigenesis. Nat Rev Cancer. 12:455–464. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Papoutsopoulou S and Janknecht R:
Phosphorylation of ETS transcription factor ER81 in a complex with
its coactivators CREB-binding protein and p300. Mol Cell Biol.
20:7300–7310. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Murphy G, Cockett MI, Ward RV and Docherty
AJ: Matrix metalloproteinase degradation of elastin, type IV
collagen and proteoglycan. A quantitative comparison of the
activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2
and punctuated metalloproteinase (PUMP). Biochem J. 277:277–279.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sires UI, Murphy G, Baragi VM, Fliszar CJ,
Welgus HG and Senior RM: Matrilysin is much more efficient than
other matrix metalloproteinases in the proteolytic inactivation of
alpha 1-anti-trypsin. Biochem Biophys Res Commun. 204:613–620.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Adachi Y, Yamamoto H, Itoh F, Arimura Y,
Nishi M, Endo T and Imai K: Clinicopathologic and prognostic
significance of matrilysin expression at the invasive front in
human colorectal cancers. Int J Cancer. 95:290–294. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tanimoto H, Underwood LJ, Shigemasa K,
Parmley TH, Wang Y, Yan Y, Clarke J and O'Brien TJ: The matrix
metalloprotease pump-1 (MMP-7, Matrilysin): A candidate
marker/target for ovarian cancer detection and treatment. Tumour
Biol. 20:88–98. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yamamoto H, Itoh F, Iku S, Adachi Y,
Fukushima H, Sasaki S, Mukaiya M, Hirata K and Imai K: Expression
of matrix metalloproteinases and tissue inhibitors of
metalloproteinases in human pancreatic adenocarcinomas:
Clinicopathologic and prognostic significance of matrilysin
expression. J Clin Oncol. 19:1118–1127. 2001.PubMed/NCBI
|
|
27
|
Sumi T, Nakatani T, Yoshida H, Hyun Y,
Yasui T, Matsumoto Y, Nakagawa E, Sugimura K, Kawashima H and
Ishiko O: Expression of matrix metalloproteinases 7 and 2 in human
renal cell carcinoma. Oncol Rep. 10:567–570. 2003.PubMed/NCBI
|
|
28
|
Rahim S, Minas T, Hong SH, Justvig S,
Çelik H, Kont YS, Han J, Kallarakal AT, Kong Y, Rudek MA, et al: A
small molecule inhibitor of ETV1, YK-4-279, prevents prostate
cancer growth and metastasis in a mouse xenograft model. PLoS ONE.
9:e1142602014. View Article : Google Scholar : PubMed/NCBI
|
